Neurology · Birmingham area, AL
Neurology studies in Birmingham area, AL
45 recruiting studies have a site in the Birmingham area. This page includes nearby cities such as Hoover, Homewood, Vestavia Hills, Bessemer.
45 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 1/Phase 2
The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
University of Alabama at Birmingham
- Location
- Birmingham, AL
- Eligibility basics
- Ages 30+
- RecruitingHealthy volunteersPhase 1
UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy
University of Alabama at Birmingham
- Location
- Birmingham, AL
- Eligibility basics
- Ages 50+
- RecruitingHealthy volunteersEarly Phase 1
Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)
University of Alabama at Birmingham
- Location
- Birmingham, AL
- Eligibility basics
- Ages 18–99
- RecruitingHealthy volunteersPhase 1
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
University of Alabama at Birmingham
- Location
- Birmingham, AL
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Birmingham, AL + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2/Phase 3
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Biohaven Therapeutics Ltd.
- Location
- Birmingham, AL + 24 other US sites
- Eligibility basics
- Ages 40–80
- Recruiting
Diagnosing Epilepsy To EffeCT Change
Epiminder America, Inc.
- Location
- Birmingham, AL + 21 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
Strategy for Improving Stroke Treatment Response
Translational Sciences, Inc.
- Location
- Birmingham, AL + 37 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi
- Location
- Homewood, AL + 31 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
- Location
- Birmingham, AL + 67 other US sites
- Eligibility basics
- Ages 50–90
- RecruitingPhase 3
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
argenx
- Location
- Birmingham, AL + 15 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
argenx
- Location
- Birmingham, AL + 12 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Pridopidine Phase 3 Study in Huntington's Disease
Prilenia
- Location
- Birmingham, AL + 8 other US sites
- Eligibility basics
- Ages 23–65
- RecruitingPhase 3
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
Kallyope Inc.
- Location
- Birmingham, AL + 111 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Sanofi
- Location
- Cullman, AL + 33 other US sites
- Eligibility basics
- Ages 18–60
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
- Location
- Birmingham, AL + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Birmingham, AL + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Celgene
- Location
- Birmingham, AL + 13 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Eli Lilly and Company
- Location
- Birmingham, AL + 34 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
- Location
- Birmingham, AL + 39 other US sites
- Eligibility basics
- Ages 21–70
- RecruitingPhase 2/Phase 3
A Study of Buntanetap in Participants With PD
Annovis Bio Inc.
- Location
- Birmingham, AL + 26 other US sites
- Eligibility basics
- Ages 40–85
- RecruitingPhase 3
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
Epygenix
- Location
- Birmingham, AL + 16 other US sites
- Eligibility basics
- Ages 2+
- RecruitingPhase 1/Phase 2
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
UniQure Biopharma B.V.
- Location
- Birmingham, AL + 15 other US sites
- Eligibility basics
- Ages 18–75
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.